# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Benny Leonard (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX008-SYN
- Date: 2026-05-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Miriam Okafor-Rosenthal, MD
- Calendar frame: modern shifted

## Subjective

The patient participates in this fictional visit for establishing primary care at 50 after a referee's license examination found high blood pressure: exertional breathlessness and chest tightness while refereeing, an ECG showing left ventricular hypertrophy, cardiovascular risk, money worries and mood, and a cardiology consultation. **S**

## Objective

Sodium: 140 mmol/L; Potassium: 4.1 mmol/L; Urea nitrogen: 15 mg/dL; Creatinine: 0.98 mg/dL; eGFR: 93 mL/min/1.73 m²; Glucose: 96 mg/dL; Hemoglobin: 14.6 g/dL; ALT: 24 U/L; HbA1c: 5.5%; TSH: 1.9 mIU/L; Urine albumin-to-creatinine ratio: 22 mg/g{creat}; Total cholesterol: 234 mg/dL (high); HDL cholesterol: 44 mg/dL; LDL cholesterol (calculated): 160 mg/dL (high); Triglycerides: 150 mg/dL (high); Lipoprotein(a): 42 nmol/L; PHQ-9: 5; GAD-7: 6; AUDIT-C: 2. All results are synthetic.

BP 164/100 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 74.6 kg; BMI 27.4 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Breathlessness and tightness across the chest on exertion for about two months, late in long nights of refereeing in hot arenas, easing within a few minutes of rest; never at rest; no fainting, palpitations, orthopnea or ankle swelling; cause under evaluation with a cardiology consultation; Stage 2 hypertension found at a yearly fitness examination for his referee's license (164/100 and 160/98 mmHg), with left ventricular hypertrophy by voltage on the ECG; untreated; home readings to follow; Hypercholesterolemia: LDL 160 mg/dL, HDL 44 mg/dL, lipoprotein(a) not raised; no diabetes. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Started: Losartan 50 mg with hydrochlorothiazide 12.5 mg, one tablet each morning **S**

## Plan

- High blood pressure: home monitoring with a validated upper-arm cuff, twice a day, with readings sent in weekly; single-pill losartan 50 mg with hydrochlorothiazide 12.5 mg from today, chosen as two first-line drugs for stage 2 hypertension and a low-cost generic; basic metabolic panel in two weeks; target below 130/80 mmHg; less salt (no more than 1,500 to 2,300 mg a day), the DASH pattern, and regular walking. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, hypertension, hyperlipidemia and ischemic heart disease monographs (2026) **S**
- Cardiology consultation for exertional breathlessness and chest tightness with left ventricular hypertrophy on the ECG: the cause, the type of hypertrophy, sudden cardiac death risk, coronary risk testing, and whether he can keep refereeing. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain (2021) **S**
- Evaluation at intake: resting ECG, basic metabolic panel, TSH, HbA1c, lipid panel, one-time lipoprotein(a) and urine albumin-to-creatinine ratio; stop and rest, and call the same day for chest discomfort at rest or lasting more than a few minutes, fainting or palpitations; referee only short undercards until the consultation. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain (2021); 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia (2026) **S**
- Money worries and mood: PHQ-9 and GAD-7 at intake and at six months; generic once-daily medicines at the lowest cost; a social needs screen; brief support and problem-solving at each visit. Guideline: Depression and Suicide Risk in Adults: Screening (2023); Anxiety Disorders in Adults: Screening (2023) **S**
